Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective

Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Catherine King, Fionnuala Cox, Anne Sloan, Patricia McCrea, J.David Edgar, Niall Conlon
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Chronic urticaria Omalizumab Self-administration Patient reported outcome measure COVID-19 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/55bf881013204d3b9915fc5d9d0dba69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55bf881013204d3b9915fc5d9d0dba69
record_format	dspace
spelling	oai:doaj.org-article:55bf881013204d3b9915fc5d9d0dba692021-11-12T04:30:00ZRapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective1939-455110.1016/j.waojou.2021.100587https://doaj.org/article/55bf881013204d3b9915fc5d9d0dba692021-10-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1939455121000818https://doaj.org/toc/1939-4551Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spontaneous urticaria and angioedema (CSU) receiving omalizumab in our centre were rapidly transitioned to home self-administration at the start of the pandemic. We conducted an anonymised patient survey after 3 months of home therapy with the aim of characterizing the patient experience throughout this period. 41 patients participated in our questionnaire (71% response rate). 93% of patients favored self-injection of omalizumab from home, with respondents citing cost savings, time savings, improved flexibility, fewer hospital visits, and less risk of exposure to COVID-19 infection as particular benefits. Concerns regarding home administration including injecting incorrectly, forgetting a dose, or having a reaction were reported very infrequently. Eighty-three percent (83%) of patients wished to continue with home therapy long-term. This survey highlights broadly positive experiences for patients rapidly transitioning to home omalizumab administration. This data will be useful to inform healthcare funders in decisions regarding patient-centred care in CSU. Facilitating home omalizumab therapy in suitable CSU patients should be strongly considered in the post-pandemic setting.Catherine KingFionnuala CoxAnne SloanPatricia McCreaJ.David EdgarNiall ConlonElsevierarticleChronic urticariaOmalizumabSelf-administrationPatient reported outcome measureCOVID-19Immunologic diseases. AllergyRC581-607ENWorld Allergy Organization Journal, Vol 14, Iss 10, Pp 100587- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chronic urticaria Omalizumab Self-administration Patient reported outcome measure COVID-19 Immunologic diseases. Allergy RC581-607
spellingShingle	Chronic urticaria Omalizumab Self-administration Patient reported outcome measure COVID-19 Immunologic diseases. Allergy RC581-607 Catherine King Fionnuala Cox Anne Sloan Patricia McCrea J.David Edgar Niall Conlon Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
description	Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spontaneous urticaria and angioedema (CSU) receiving omalizumab in our centre were rapidly transitioned to home self-administration at the start of the pandemic. We conducted an anonymised patient survey after 3 months of home therapy with the aim of characterizing the patient experience throughout this period. 41 patients participated in our questionnaire (71% response rate). 93% of patients favored self-injection of omalizumab from home, with respondents citing cost savings, time savings, improved flexibility, fewer hospital visits, and less risk of exposure to COVID-19 infection as particular benefits. Concerns regarding home administration including injecting incorrectly, forgetting a dose, or having a reaction were reported very infrequently. Eighty-three percent (83%) of patients wished to continue with home therapy long-term. This survey highlights broadly positive experiences for patients rapidly transitioning to home omalizumab administration. This data will be useful to inform healthcare funders in decisions regarding patient-centred care in CSU. Facilitating home omalizumab therapy in suitable CSU patients should be strongly considered in the post-pandemic setting.
format	article
author	Catherine King Fionnuala Cox Anne Sloan Patricia McCrea J.David Edgar Niall Conlon
author_facet	Catherine King Fionnuala Cox Anne Sloan Patricia McCrea J.David Edgar Niall Conlon
author_sort	Catherine King
title	Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
title_short	Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
title_full	Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
title_fullStr	Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
title_full_unstemmed	Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
title_sort	rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the covid-19 pandemic: a patient perspective
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/55bf881013204d3b9915fc5d9d0dba69
work_keys_str_mv	AT catherineking rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT fionnualacox rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT annesloan rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT patriciamccrea rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT jdavidedgar rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective AT niallconlon rapidtransitiontohomeomalizumabtreatmentforchronicspontaneousurticariaduringthecovid19pandemicapatientperspective
_version_	1718431291477590016

Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective

Ejemplares similares